A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy

Allergan4,385 enrolled

Overview

This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.

Study Type

OBSERVATIONAL

Enrollment

4,385

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

Any Fixed Combination TherapyDRUG

Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of glaucoma or ocular hypertension * Previously treated with monotherapy followed by fixed combination therapy for at least 12 weeks Exclusion Criteria: * None

Locations (1)

Unnamed facility

Madrid, Spain

Outcomes

Primary Outcomes

Change From Baseline in Intraocular Pressure (IOP)

IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.

Time frame: Baseline, 12 Weeks

Secondary Outcomes

Patient Assessment of Tolerability Using a 4-Point Scale

Patient assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The percentage of patients assessed as good and very good combined are reported.

Time frame: 12 Weeks

Physician Assessment of Tolerability Using a 4-Point Scale

Physician assessment of tolerability using a 4-point scale (very good, good, moderate, and poor). The percentage of patients assessed as good and very good combined are reported.

Time frame: 12 Weeks

Percentage of Patients Who Maintained Better Compliance With Treatment

Percentage of patients who maintained better compliance with treatment than prior therapy was assessed by the patient on a 3-point scale (better, equal, and worse compliance).

Time frame: 12 Weeks

Percentage of Patients Continuing on Therapy After 12 Weeks

Percentage of patients continuing on therapy after 12 weeks was assessed as Yes or No.

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.